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Abstract 
Aims 
Previously, low high-density lipoprotein (HDL) cholesterol was found to be one of the strongest 
predictors of mortality and/or heart failure (HF) hospitalisation in patients with HF. We therefore 
performed in-depth investigation of the multifunctional HDL proteome to reveal underlying 
pathophysiological mechanisms explaining the association between HDL and clinical outcome. 
Methods and results 
We selected a cohort of 90 HF patients with 1:1 cardiovascular death/survivor ratio from BIOSTAT-
CHF. A novel optimised protocol for selective enrichment of lipoproteins was used to prepare plasma. 
Enriched lipoprotein content of samples was analysed using high resolution nanoscale liquid 
chromatography-mass spectrometry-based proteomics, utilising a label free approach. Within the 
HDL proteome, 49 proteins significantly differed between deaths and survivors. An optimised model 
of 12 proteins predicted death with 76% accuracy (Nagelkerke R2 = 0.37, P-value < 0.001). The 
strongest contributors to this model were filamin-A (related to crosslinking of actin filaments) (OR 
0.31, 95% CI 0.15 – 0.61, P = 0.001) and pulmonary surfactant-associated protein B (related to 
alveolar capillary membrane function) (OR 2.50, 95% CI 1.57 – 3.98, P < 0.001). The model 
predicted mortality with an area under the curve of 0.82 (95% CI 0.77 – 0.87, P < 0.001). Internal 
cross validation resulted in 73.3 ± 7.2% accuracy. 
Conclusion 
This study shows marked differences in composition of the HDL proteome between HF survivors and 
deaths. The strongest differences were seen in proteins reflecting crosslinking of actin filaments and 
alveolar capillary membrane function, posing potential pathophysiological mechanisms underlying 
the association between HDL and clinical outcome in HF.  
Key words: heart failure; high-density lipoprotein; proteome 
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Abbreviations 
AHSG   Alpha-2-HS-Glycoprotein 
APOA1  Apolipoprotein A-I 
APOA2  Apolipoprotein A-II 
APOC3  Apolipoprotein C-III 
B2M   Beta-2-Microglobulin 
BIOSTAT-CHF A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure 
BNP   Brain Natriuretic Peptide 
eGFR   Estimated Glomerular Filtration Rate 
EPHX1  Epoxide Hydrolase 1 
F10   Coagulation Factor X 
FLNA   Filamin-A 
HDL   High-density Lipoprotein 
LVEF   Left Ventricular Ejection Fraction 
MST1   Macrophage-stimulating protein 
NT-proBNP  N-Terminal Pro Brain Natriuretic Peptide 
NYHA   New York Heart Association 
PON1   Serum paraoxonase/arylesterase 1 
SFTPB   Pulmonary Surfactant-Associated Protein B  
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Introduction  
Several studies showed that lower high-density lipoprotein (HDL) cholesterol was associated with a 
higher incidence of heart failure (HF),1 worsening of HF,2 and mortality and HF hospitalisation in 
patients with established HF.2–5 We recently studied predictors of clinical outcome in two large 
European cohorts of patients with HF (BIOSTAT-CHF). Low HDL-cholesterol was found to be 
amongst the strongest independent predictors of death and/or HF hospitalisation.6 The exact 
pathophysiological mechanisms underlying the association between HDL and HF are however 
unknown.  
Technological developments and the use of mass spectrometry have strongly increased our 
understanding of the proteomic diversity of HDL. Besides the well-known function in reverse 
cholesterol transport, HDL carries many other constituents. Previous studies have identified over 90 
proteins that are consistently co-expressed in variable amounts attached to HDL particles, consisting 
of apolipoproteins, lipid transfer proteins, enzymes, acute-phase response proteins, complement 
components, haemostasis proteins and several others. The functions of HDL are therefore multifold: it 
possesses anti-inflammatory, antioxidant, anti-infective, antithrombotic, and atheroprotective 
capacities and exerts effects on endothelial function.7 
We hypothesised that further in-depth investigation of the multifunctional HDL proteome could 
reveal possible underlying pathophysiological mechanisms of HDL in HF that can help us understand 
its clinical value in HF. Therefore, this study aims to investigate differences in HDL proteome 
composition in HF that relate to a worse prognosis in HF. 
 
Materials & Methods 
Patient population 
This study was conducted with patients selected from the A systems BIOlogy Study to TAilored 
Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort, which has been described in detail 
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before.8 In brief, BIOSTAT-CHF was an investigator-driven multicentre clinical study consisting of 
2516 patients which aimed to identify patients with a poor outcome despite currently recommended 
treatment using a systems biology approach that incorporates demographics, gender, biomarkers, 
genetics and proteomics. Patients were included after presentation with either new onset or worsening 
HF, which was confirmed by left ventricular ejection fraction (LVEF) ≤ 40% and/or brain natriuretic 
peptide (BNP) > 400 pg/mL or N-terminal pro brain natriuretic peptide (NT-proBNP) > 2000 pg/mL. 
All patients recruited in BIOSTAT-CHF gave written informed consent to participate in the study. 
BIOSTAT-CHF was conducted in concordance with the declaration of Helsinki, national ethics and 
legal requirements, as well as relevant EU legislation. The study was approved by national and local 
ethics committees. 
For this study, 90 patients from BIOSTAT-CHF were selected for a discovery cohort and matched 
with a 1:1 death/survivor ratio of cardiovascular (CV) cause within a follow-up period of 12 months. 
Patients were furthermore matched for important prognostic criteria. The matching criteria and 
randomisation procedure are shown in supplementary material (Appendix 1).  
Sample preparation 
The detailed sample preparation protocol has been included in supplementary material (Appendix 2). 
Lipoproteins were isolated using calcium silicate matrix (commercial name Lipid Removal Agent 
(LRA), Sigma-Aldrich, St Louis, MO, USA), to separate them from other abundant proteins in plasma 
which will impair proteomic analysis. Prior to trypsin digestion, disulphide bonds were reduced using 
tris (2-carboxyethyl) phosphine (TCEP, Sigma-Aldrich), cysteines alkylated by iodoacetamide (IAA, 
Sigma-Aldrich), following denaturation using ammonium deoxycholate (ADC, 0.5%, deoxycholic 
acid treated with neat ammonium hydroxide, Sigma-Aldrich), thus allowing trypsin maximum access 
to the cleavage sites within the protein and preventing renaturation. Trypsin (Sigma-Aldrich) was 
added and the samples were incubated at 37 °C for 16h. Trypsin digestion was stopped by lowering 
the pH of the sample with a volume of fully concentrated formic acid (FA, final concentration 1%, 
Sigma-Aldrich). Salts and other undesired impurities were eliminated by solid phase extraction (SPE) 
on EMPORE C18 discs. A semi-pooled sample was created from 10 random samples of the discovery 
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cohort to serve as a Quality Control (QC) sample. The QC samples were treated equal to the other 
samples.  
Samples were reconstituted in purified water containing FA (0.1%) and spiked with an internal 
standard, MassPREP™ yeast alcohol dehydrogenase (ADH, Waters Corporation, Manchester, UK), 
with a known amount of 50 fmol injected for each run; 1 µL of sample was injected. All samples were 
analysed in triplicate. A QC was run in triplicate after each batch of 10 samples with an injection 
volume of 1 µL for each single run. In between each patient or QC, washings were performed with 
three different cleaning mixtures that contained isopropyl alcohol, methanol, and FA respectively.   
Nanoscale Liquid Chromatography (LC)-coupled Mass Spectrometry  
Each sample was analysed on a Waters NanoAcquity system (Waters Corporation, Milford, MA, 
USA). The LC system was coupled to a Waters Synapt G2S HDMS (Waters Corporation, Milford, 
MA, USA). Data were acquired using MassLynx 4.1. Details on the settings and methodology that 
were implemented are described in supplementary material (Appendix 3).  
Data analysis 
Raw data were interrogated by Progenesis QI software (Nonlinear Dynamics, Gateshead, UK) for data 
analysis. A description of the used search criteria is included in supplementary material (Appendix 3).  
Progenesis QI executed label-free quantification of the identified proteins using the Hi-N3 method as 
first described by Silva et al.9 Since the samples were internally spiked, this allowed for both Hi-N 
relative quantification and Hi-N absolute quantification. Analyses were focused on Hi-N relative 
quantification, with the Hi-N absolute quantification method serving as a verification back-up if 
needed.   
Statistical analysis 
Descriptive statistics were used to examine the relationship of the two groups with clinical variables. 
Prior to analyses, the distribution of all variables was checked. Data are presented as mean ± SD when 
normally distributed, as median (interquartile range) for skewed variables and as frequencies 
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(percentage) for categorical variables. A p-value of < 0.05 was considered statistically significant. 
Continuous normally distributed variables were tested with the student independent t-test or analysis 
of variance (ANOVA), whereas skewed variables were tested using the Kruskal-Wallis H test. 
Categorical variables were tested with Chi-Squared tests. To adjust for multiple testing, a false 
discovery rate of 1% was implemented for biomarker selection. Different search techniques (logistic 
regression and orthogonal projections to latent structures-discriminant analysis (OPLS-DA)) were 
used to establish an optimised model among significant proteins for death prediction. Logistic 
regression analysis of this optimised model was adjusted for age, sex, trigger event, trigger reason, 
LVEF, estimated glomerular filtration rate (eGFR), and CV death risk score, which are explained in 
further detail in Appendix 1.  Statistical tests were performed with IBM SPSS Statistics version 23. 
SIMCA version 14 (MSK Umetrics, Sweden) was used to perform principal component analysis 
(PCA) and construct the S-plot. Internal cross validation was performed using RapidMiner software 
version 7.4 for candidate biomarkers. Gene Ontology analysis of proteins was executed using the 
Protein ANalysis THrough Evolutionary Relationships (PANTHER) Classification System version 
11.1.10 
 
Results 
Patient characteristics 
Patient characteristics of the two groups are displayed in Table 1. Mean age was 70.0 ± 9.3 in the 
patients who survived and 69.9 ± 8.8 years in the patients who died. In both groups, most patients 
were men (87%), most patients had a NYHA classification of III/IV (87% and 78% for survivors and 
deaths respectively), and HDL cholesterol levels were higher in the survivors group (1.1 (1.0 – 1.3) 
mmol/L, as opposed to 0.8 (0.7 – 1.1) mmol/L in deaths, P = 0.004). All other patient characteristics 
were not significantly different between the two groups. Mean study participation time was 787.0 ± 
137.6 days for survivors and 151.7 ± 98.7 days for deaths. 
Principal component analysis 
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The separation of the HDL proteomes of survivors and deaths is indicated in Figure 1. Each point on 
the plot represents a patient’s proteome profile (either deceased or survivor) based on the patient 
sample analysis in triplicate. The principal component analysis is also displayed in 2D in 
Supplementary Figure 1. 
HDL proteome biomarkers selection 
A total of 647 proteins with quantification were identified from both groups and compared. Out of all 
reported HDL proteins, as documented by the HDL Proteome Watch (initiated by the Davidson Lab, 
Cincinnati, OH; database version 14/8/2015), abundances of 49 HDL proteins were significantly 
different between deaths and survivors (Supplementary Table 1). Gene Ontology analysis of these 
proteins revealed involvement in multiple biological processes, such as cellular processes (e.g. cell 
communication), biological regulation (e.g. homeostatic process), metabolic processes (e.g. lipid 
metabolism, protein metabolic process), and response to stimulus (e.g. immune response, response to 
stress), as shown in Supplementary Figure 2.  
An optimised model featuring 12 selected proteins was established, using different search techniques, 
to predict death. These 12 proteins included coagulation factor X (F10), epoxide hydrolase (EPHX1), 
filamin-A (FLNA), macrophage-stimulating protein (MST1; also called hepatocyte growth factor-like 
protein), pulmonary surfactant-associated protein B (SFTPB), and serum paraoxonase/arylesterase 1 
(PON1) based on multiple regression analysis, and alpha-2-HS-glycoprotein (AHSG; also called 
fetuin-A), apolipoprotein A-I (APOA1), apolipoprotein A-II (APOA2), apolipoprotein C-III 
(APOC3), beta-2-microglobulin (B2M), and kallistatin (also called Serpin A4) based on OPLS-DA 
using a Variable Importance in Projection (VIP)-value >1 as cut-off value (data not shown). An 
overview with details on the proteins is provided in Table 2. 
Multiple logistic regression analysis of this set of proteins resulted in an ability to predict death with 
76% accuracy (Nagelkerke R2 = 0.365, P-value for the model < 0.001). Table 3 shows the 
contribution of each protein to the prediction model, after correcting for the matching criteria. The 
proteins that significantly contributed to the prediction of death were SFTPB (OR 2.50, 95% CI 1.57 – 
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3.98, P < 0.001), FLNA (OR 0.31, 95% CI 0.15 – 0.61, P = 0.001), APOA1 (OR 0.43, 95% CI 0.25 – 
0.73, P = 0.002), EPHX1 (OR 3.15, 95% CI 1.54 – 6.44, P = 0.002), PON1 (OR 0.55, 95% CI 0.35 – 
0.88, P = 0.013), and F10 (OR 2.09, 95% CI 1.10 – 3.94, P = 0.024). Associations of FLNA and 
SFTPB with structural and functional parameters and biomarkers are presented in Supplementary 
Table 2. 
To further confirm the value of the selected proteins, a S-plot was drafted (as presented in Figure 2) to 
provide a graphical representation of both the covariance and correlation structure between the 
selected proteins and the predictive score for death. 
In linear regression analysis, these 12 proteins significantly predicted HDL cholesterol (P < 0.001), 
resulting in R2 = 0.579.   
When a receiver operating characteristic (ROC) curve was plotted for all selected proteins combined, 
this resulted in an AUC of 0.820 (95% CI 0.768 – 0.872, P < 0.001) and a maximum sensitivity and 
specificity of 0.763 and 0.756 respectively. 
Internal cross validation resulted in 73.3 ± 7.2% accuracy. 
Discussion 
In the present study, we demonstrate that the HDL proteome is different in heart failure patients who 
survived and those who died. The strongest differences were seen in proteins reflecting crosslinking 
of actin filaments and alveolar capillary membrane function. These marked differences in HDL-
proteome composition between deaths and survivors might reveal the pathophysiological mechanisms 
underlying the association between HDL and clinical outcome in HF.  
Previous studies investigating the HDL proteome in HF observed differences in proteome profiles 
between healthy subjects and HF patients and proteome profiles in HF patients associated with 
immune response.11,12 Additionally, diminished anti-inflammatory,13 antioxidant activity,13–15 and 
cholesterol efflux capacity16 of HDL have been implicated in HF and predicted adverse events. The 
present study is the first to investigate differences in HDL proteome profiles related to clinical 
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outcome in HF in a larger, well-characterised HF patient population with well-matched subgroups, 
utilising state-of-the-art nanoscale liquid chromatography-coupled mass spectrometry and powerful 
informatics to analyse the data. 
Out of 49 HDL proteins that significantly differed between deaths and survivors, we selected 12 
proteins to predict death based on multiple statistical approaches. These 12 proteins notably reflected, 
among others, processes related to atherogenesis, inflammation, and oxidative stress. Not much is 
known about their association with HF (outcome), but alpha-2-HS-glycoprotein (also called fetuin-A) 
levels were found to be lower in chronic HF patients,17 lower levels of ApoA1 have been associated 
with worse prognosis in HF,4,5 higher beta-2-microglobulin levels have been proposed a 
cardiovascular risk marker in HF,18 and decreased PON1 activity and levels have been associated with 
HF and adverse outcomes in HF.13,14,19 We will elaborate on FLNA, SFTPB, and ApoC3 in the next 
section. 
The strongest contributors to the prediction model were filamin-A (FLNA) and pulmonary surfactant-
associated protein B (SFTPB). We realise that the presence of these proteins in the HDL proteome is 
not direct proof for their presence in the heart, or for signalling in the heart, but nevertheless believe 
their presence may have functional consequences to the heart related to the associations we describe. 
First, FLNA is an actin-binding protein that plays a role in cell signalling functions, such as cell 
migration and organ development. Deficiency of FLNA is, among others, associated with severe 
cardiac malformation, suggesting an important function of FLNA in cardiac morphogenesis.20 In a 
mouse model, endothelial deletion of FLNA resulted in a defective endothelial response and increased 
scar formation, leading to worse myocardial infarction-induced left ventricular dysfunction.21 These 
unfavourable effects of FLNA deficiency appear to be reflected by the decreased abundances of 
FLNA in deaths in our study. 
Second, higher levels of SFTPB in deaths could be explained by the presence of increased alveolar 
membrane damage in a worse HF disease state due to increased pulmonary pressure, resulting in 
oedema and subsequently in dyspnoea in HF. Levels of surfactant proteins in plasma, especially 
SFTPB, are suitable biomarkers to assess lung health and alveolar capillary membrane function, 
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because when damaged, surfactant proteins move into the blood.22–24 It is thus logical for SFTPB to be 
higher in a worse HF disease state (reflecting increased congestion), which has moreover been shown 
in HF before.25 Whether the HDL-bound portion of SFTPB compared to SFTPB levels in plasma is a 
better predictor of HF outcome is difficult to say since it is not entirely clear what portion of the total 
amount of SFTPB binds to HDL, but in a previous study investigating the HDL proteome in end-stage 
renal disease patients, HDL-bound SFTPB was associated with ESRD, while its plasma counterpart 
was comparable between ESRD patients and CKD stage 4 patients.26 It is thus possible for the SFTPB 
HDL-bound portion to be different from its plasma counterpart, which could possibly also be the case 
in different HF disease states. 
Although most findings in this study are in line with the expected observations, an unexpected finding 
was that ApoC3 levels were lower in deaths. Previous studies repeatedly showed that higher ApoC3 
levels are consistent with higher cardiovascular event rates due to its atherogenic effects. This has 
however predominantly been investigated for non-HDL lipid particles (LDL and very low density 
lipoprotein (VLDL)) and total plasma; data on HDL ApoC3 are too limited and inconsistent to 
confirm that the same is true for these particles.27 However, as explained further on, a satisfactory 
explanation for this finding remains uncertain due to recovery of all lipoproteins by the used 
methodology. 
Strengths and limitations of the study 
This is the first study investigating HDL proteome composition in relation to clinical outcome in 
patients with HF. The lipoprotein isolation method that was used in this study proved to be highly 
suitable for addressing the aim of this study; we were able to detect 88.4% out of the total number of 
confident HDL proteins.  
Furthermore, use of UPLC-HDMSE as a means to analyse proteins ensured high selectivity, 
specificity and confidence. The methods of this study proved to be time-efficient, high-throughput, 
reproducible, capable of working with complex samples and inexpensive (both the sample preparation 
procedure and the label-free quantification approach). Reliability of the MS runs was ensured by 
running quality controls and Hela cell extract and, on top of that, use of powerful informatics to 
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analyse the raw data. Finally, the well-matched groups ensured suitable circumstances for discovery 
purposes.   
The fact that the survivors and the deaths groups were so well matched could however also pose a 
limitation: after correction for important influential factors such as age and severity of HF in a non-
matched patient cohort, the HDL proteome may lose some of its predictive value. The matching used 
in this study cohort also limited analysis of the additive value of the HDL proteome on top of the 
recently constructed BIOSTAT risk score,6 since the groups were already matched on some of the 
variables present. 
Also, the results of this study only apply to patients of Caucasian ethnicity and HF patients with a 
reduced ejection fraction.   
Furthermore, the lipid affinity matrix used in this study does not have specific affinity for HDL alone 
and other lipid subclasses could have potentially influenced the measured apolipoprotein amounts to 
some extent. 
Finally, only 49 patients had available HDL cholesterol measurements. However, we do not know 
whether the HDL protein to cholesterol ratio is similar for every patient, which is why there is no 
indication to say that this has certainly influenced our results. Furthermore, we have loaded equal total 
peptide amounts on the LC-MS/MS for each sample. As a surrogate for HDL cholesterol, ApoA1 is 
often used. We see in our analysis that ApoA1 is lower in deaths in univariate and multivariate 
analysis, which is in line with the association between lower HDL cholesterol and adverse outcome in 
HF in the BIOSTAT-CHF study. 
In order to address some limitations of this study, the following studies could be carried out: a) a 
validation study to confirm the findings of this study in another study population; b) a study 
investigating the relationship between HDL functionality in relation with HDL proteome content and 
in relation to prognosis in HF; c) a validation of the total plasma content of FLNA and SFTPB where 
bound and free fractions can be calculated and independently related to outcomes, and d) addition of 
HF hospitalisation as an endpoint. 
Conclusions and implications 
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This study shows that abundances of proteins with multiple important functions that reflect, among 
others, atherogenesis, inflammation, and oxidative stress, are altered in the HDL proteome of patients 
with a worse HF disease state. The strongest differences were seen in proteins reflecting crosslinking 
of actin filaments and alveolar capillary membrane function. Therefore, HDL could be a proxy for 
these processes implicated in HF pathophysiology which might explain the association between low 
HDL and increased risk of mortality and/or hospitalisation in patients with HF.  
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Figure Legends 
 
Figure 1. Principal component analysis of the HDL proteomes of survivors and deaths  
SIMCA14 was used to generate a 3D plot based on the OPLS-DA scores. Each data point represents a 
sample in the data. Each green point on the plot represents a survivor’s proteome profile and each 
blue point represents a deceased patient’s proteome profile, showing the separation of proteome 
profiles between survivors and deaths. 
 
Figure 2. S-plot of HDL proteins 
SIMCA14 was used to generate this figure based on OPLS-DA scores for putative biomarker 
identification. In this figure, the p1-axis (x-axis) describes the magnitude of each variable in the data 
and the p(corr)1-axis (y-axis) represents the reliability of each variable in the data. The selected 
proteins are indicated in red while the remaining significantly different proteins between deaths and 
survivors are indicated in green. Abbreviations: AHSG, alpha-2-HS-glycoprotein; APOA1, 
apolipoprotein A-I; APOA2, apolipoprotein A-II; APOC3, apolipoprotein C-III; B2M, beta-2-
microglobulin; EPHX1, epoxide hydrolase 1; F10, coagulation factor X; FLNA, filamin-A; MST1, 
macrophage-stimulating protein; PON1, serum paraoxonase/arylesterase 1; SERPINA4, kallistatin; 
SFTPB, pulmonary surfactant-associated protein B.   
 
Figure 3. ROC curve for prediction of death 
Blue curve represents all 12 selected proteins combined.  
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Appendix 1. Patient matching and randomisation procedure 
Patient matching 
Patients were matched for important prognostic criteria including age (within 5 years difference), sex 
(exact matching), trigger event (exact matching), trigger reason (exact matching), LVEF (within 10% 
difference), eGFR, as calculated by the MDRD formula (within 50 mL min-1/1.73 m2 difference, 
notional), and a risk score for CV death (regression-based score which included age, sex, eGFR, HF 
aetiology (ischaemic vs non-ischaemic), body mass index (BMI), HF hospitalisation within the year 
preceding recruitment, and New York Heart Association (NYHA) class; it was generated following 
multiple imputation using chained equations, creating five imputed datasets, after which the analysis 
was repeated for each dataset and residuals from each of the five models averaged to generate a final 
risk score for each individual that had to be within 0.25 difference between groups). 
Additional criteria that were implemented for patient selection included ischemic aetiology and 
Caucasian ethnic origin, to reduce heterogeneity between study groups. In order to ensure data 
availability for patient matching and/or subsequent analyses, all patients entering selection were 
required to have a clear description of the reason for recruitment, and availability of data for NYHA 
class, eGFR, BMI, BNP and LVEF. To improve data quality, patients were also required to be 
concordant with all study criteria, have a recent echocardiogram and an exact date of death recorded 
(where applicable). 
Randomisation procedure 
After the selection of patients all samples were allocated a randomised “Discovery ID”, which was 
achieved as follows: 
First, a list of BIOSTAT-CHF ‘Patient IDs’ was generated for discovery samples that were ‘cases’ 
and sorted into numerical order. The order of this list was then randomised using the ‘List 
Randomizer’ available at: https://www.random.org and these samples were paired with their matched 
‘controls’ to generate case/control units (CCUs). A list of integers of either 1 or 2 was then generated 
using the ‘Random Integer Generator’. Consequently, the samples from the CCUs were placed in a 
single list in the randomised order, with the integers 1 and 2 determining whether the case (1) or 
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control (2) entered the list first. Finally, samples were allocated a “Discovery ID” in ascending order 
from the randomised list order. This method of randomisation ensured that when processed in 
“Discovery ID” order, every 2 samples contains a case with its matched control, but this did not 
follow a predictable pattern of case, control, case, control, etc. 
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Appendix 2. Protocol for MS sample preparation 
1. Bind 50 µL plasma to 100 µL of 3 times pre-washed LRA (100 mg/mL stock solution) in 50 
mM ammonium bicarbonate for 1 hour. 
2. Wash tube in ammonium bicarbonate 5 times. 
3. Add 10 mM TCEP at 60°C for 5 minutes. 
4. Add 15 mM IAA at room temperature for 30 minutes in the dark. 
5. Add 0.5% ADC for 30 minutes at 60°C. 
6. Add trypsin 1:50 (trypsin to total expected amount of protein, calculated in weight of protein 
per tube) and incubate overnight at 37°C on a shaker plate. Approximate 4 mg of protein is assumed 
to be present in each sample. 
7. Stop the trypsin by adding fully concentrated formic acid (FA, final concentration 1%).   
8. Spin the sample hard and take off the peptides in the supernatant.  
9. Empore samples to get rid of the salts. First, clean the columns with 1 mL of methanol and 
subsequently by 4 times 1 mL of 0.1% FA in water. Then load the samples onto the column to extract 
the peptides and subsequently wash with another 5 times 1 mL of 0.1% FA. Elute the extracted 
peptides with 0.9 mL of 60% acetonitrile (ACN) + 0.1% FA and 0.9 mL of 80% ACN + 0.1% FA and 
collect in 5 mL tubes. 
10. Split the sample into 2 tubes, put one in freezer at -80ºC to serve as a back-up. 
11. Speed vacuum the other tube for 2 hours. 
12. Freeze dry overnight. 
13. Suspend in 20 µL of purified water. 
14. Perform a peptide assay. 
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15. Take 10 µL of the sample and mix with 10 µL 100 fmol ADH (made up in 0.2% FA in 
purified water), thus resulting in 50 fmol ADH in 0.1% FA (in purified water) per sample.  
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Appendix 3. Nanoscale liquid chromatography-coupled mass spectrometry  
Nanoscale liquid chromatography(LC) 
The peptides were initially loaded onto a Symmetry C18 180 μm x 20 mm 5 μm trap column to desalt 
and chromatographically focus the peptides prior to elution onto a HSS T3 C18 75 μm x 150 mm, 1.7 
μm analytical column. Solvent A: HPLC grade water with 0.1% formic acid and Solvent B: 
Acetonitrile with 0.1% formic acid was used. The flow rate was set at 0.3 µL/min. The gradient began 
following a 3 min (5 µL/min) trapping stage on the trap column. At time zero, A was 99% while B 
was 1%. B increased linearly to 40% at 90 min and to 85% at 92 min. The gradient was held at 85% B 
at 93 min and returned to starting conditions at 95 mins to equilibrate. 
Mass spectrometry 
The instrument was run in positive ion nanoelectrospray ionisation mode. Capillary voltage was set at 
3.4 kV and cone voltage at 30 V. Picotip emitters (10 µm internal diameter, Presearch, Basingstoke, 
UK) were used for the nanostage to direct flow from the analytical column through to the source. A 
helium gas flow of 180mL/min and ion mobility (IM) separator gas flow (N2) of 90 mL/min with a 
pressure of 2.5 mbar was used.  An IM wave velocity of 600 m/s and wave height of 40 V was used 
throughout each run. During LC-IM-DIA-MS low collision-induced dissociation (CID) energy, 2 V 
was applied across the transfer ion guide. During high CID energy, a ramp of 27-50 V was applied. 
Argon was used as CID gas. Lockspray of [Glu1]-Fibrinopeptide (GFP) m/z at 785.84265 was used to 
maintain mass accuracy throughout the chromatographic run.  
Search criteria for data analysis 
Search criteria assumed trypsin digestion and included carbamidomethyl C as a fixed modification 
and deamidation N, oxidation M, and phorphoryl STY as variable modifications. The allowed number 
of missed cleavages was set to 2, minimal fragment ion matches per peptide and minimal fragment 
ion matches per protein was set to 2 and 5 respectively, minimal peptide matches per protein was set 
to 2, maximum hits to return was set to 20, and maximum protein mass was set to 1000 kDa. A false 
discovery rate of 1% was implemented. Processing parameters included 785.84265 Da as the set lock 
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mass, lock mass window 0.25, low energy threshold 150 counts, elevated energy threshold 25 counts, 
and intensity threshold 750 counts. These processing parameters were determined by optimisation 
using Protein Lynx Global Server Threshold Inspector (Waters Corporation, Manchester, UK).  
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Table 1. Baseline characteristics of the BIOSTAT-CHF discovery cohort 
Characteristics Survivors 
(n = 45) 
Deaths 
(n = 45) 
P-value 
Age (years) 70.0 ± 9.3 69.9 ± 8.8 0.963 
Male sex, n (%) 39 (87) 39 (87) 1.000 
BMI (kg/m2) 28.2 ± 4.8 27.5 ± 6.2 0.524 
NYHA class III/IV, n (%) 39 (87) 35 (78) 0.524 
LVEF (%) 28.0 ± 5.7 26.3 ± 7.2 0.221 
Systolic blood pressure (mmHg) 124.5 ± 23.6 118.5 ± 21.3 0.210 
Diastolic blood pressure (mmHg) 73.8 ± 13.7 72.3 ± 11.3 0.576 
Heart rate (bpm) 76 ± 20 79 ± 15 0.440 
BNP (pg/mL) 409.3 (162.0 – 573.2) 488.4 (230.5 – 766.5) 0.255 
eGFR (ml/min-1) 56.3 ± 17.2 53.2 ± 21.1 0.455 
Serum creatinine (µmol/L) 114.0 (98.0 – 133.9) 124.0 (99.7 – 163.5) 0.296 
Total cholesterol (mmol/L)* 3.7 (3.3 – 4.5) 3.2 (2.8 – 4.2) 0.070 
HDL cholesterol (mmol/L)** 1.1 (1.0 – 1.3) 0.8 (0.7 – 1.1) 0.004 
LDL cholesterol (mmol/L)*** 2.2 (1.7 – 3.2) 1.8 (1.5 – 2.8) 0.092 
Diabetes, n (%) 20 (44) 18 (40) 0.670 
Hypertension, n (%) 34 (76) 27 (60) 0.114 
Reason for visit, n (%) 
- New onset of HF 
- Worsening HF 
 
3 (7) 
42 (93) 
 
3 (7) 
42 (93) 
 
1.000 
BMI, body mass index; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL, high 
density lipoprotein; HF, heart failure; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; 
NYHA, New York Heart Association.  
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* Data only available for 54 patients (28 survivors; 26 deaths) 
** Data only available for 49 patients (26 survivors; 23 deaths) 
*** Data only available for 48 patients (25 survivors; 23 deaths) 
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Table 2. Proteins associated with clinical outcome in HF as selected by multiple approaches 
Protein Function Higher or 
lower in 
deaths 
Fold change P-value 
Alpha-2-HS-glycoprotein Negative acute 
phase reactant 
Lower 1.18 0.014 
Apolipoprotein A-I Anti-atherogenic, 
antioxidant, anti-
inflammatory 
Lower 1.16 <0.001 
Apolipoprotein A-II Anti-atherogenic, 
antioxidant 
Lower 1.28 0.022 
Apolipoprotein C-III Pro-atherogenic Lower 1.58 0.008 
Beta-2-microglobulin Indicator of 
immune activation 
Higher 1.17 0.045 
Coagulation factor X Coagulation Higher 1.22 0.021 
Epoxide hydrolase 1 Detoxification Higher 1.17 0.008 
Filamin-A Crosslinks actin 
filaments 
Lower 1.19 0.011 
Kallistatin Antioxidant, anti-
inflammatory, 
anti-fibrotic 
Lower 1.27 <0.001 
Macrophage-stimulating 
protein 
Stress response, 
pro-apoptotic 
Lower 1.26 0.034 
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Pulmonary surfactant-
associated protein B 
Assembly of 
pulmonary 
surfactant 
Higher 1.39 0.006 
Serum 
paraoxonase/arylesterase 1 
Anti-atherogenic, 
antioxidant, anti-
inflammatory 
Lower 1.20 0.006 
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Table 3. Multiple logistic regression model for prediction of death 
Protein B Wald P-value Odds ratio (95% CI) 
Alpha-2-HS-glycoprotein -0.161 0.143 0.706 0.85 (0.37 – 1.96) 
Apolipoprotein A-I -0.846 9.926 0.002 0.43 (0.25 – 0.73) 
Apolipoprotein A-II 0.014 0.002 0.962 1.01 (0.58 – 1.77) 
Apolipoprotein C-III -0.159 0.513 0.474 0.85 (0.55 – 1.32) 
Beta-2-microglobulin 0.370 1.751 0.186 1.45 (0.84 – 2.50) 
Coagulation factor X 0.735 5.123 0.024 2.09 (1.10 – 3.94) 
Epoxide hydrolase 1 1.147 9.875 0.002 3.15 (1.54 – 6.44) 
Filamin-A -1.186 11.350 0.001 0.31 (0.15 – 0.61) 
Kallistatin -0.285 1.225 0.268 0.75 (0.45 – 1.25) 
Macrophage-stimulating 
protein  
-0.198 0.626 0.429 0.82 (0.50 – 1.34) 
Pulmonary surfactant-
associated protein B 
0.916 14.917 <0.001 2.50 (1.57 – 3.98) 
Serum 
paraoxonase/arylesterase 1 
-0.592 6.216 0.013 0.55 (0.35 – 0.88) 
 
  
 33 
Figure 1. Principal component analysis of the HDL proteomes of survivors and deaths 
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Figure 2. S-plot of HDL proteins
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Figure 3. ROC curve for prediction of death 
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Supplementary material 
Supplementary Table 1. All significantly different HDL proteins between deaths and survivors  
 
Accession 
number 
Protein Highest 
condition 
Fold 
change 
P-value 
Q9HDC9 Adipocyte plasma membrane-
associated protein 
Deaths 1.12 0.027 
P19652 Alpha-1-acid glycoprotein 2  Survivors 1.12 0.041 
P01011 Alpha-1-antichymotrypsin Deaths 1.13 0.001 
P01009 Alpha-1-antitrypsin Deaths 1.21 <0.001 
P04217 Alpha-1B-glycoprotein Deaths 1.15 0.004 
P02765 Alpha-2-HS-glycoprotein  Survivors 1.18 0.014 
P01023 Alpha-2-macroglobulin  Deaths 1.09 0.007 
P02647 Apolipoprotein A-I  Survivors 1.16 <0.001 
P02652 Apolipoprotein A-II  Survivors 1.28 0.022 
P04114 Apolipoprotein B-100  Deaths 1.07 0.020 
P02656 Apolipoprotein C-III  Survivors 1.58 0.009 
P61769 Beta-2-microglobulin  Deaths 1.17 0.045 
P00450 Ceruloplasmin  Deaths 1.22 <0.001 
P12259 Coagulation factor V  Deaths 1.15 0.019 
P00742 Coagulation factor X  Deaths 1.22 0.022 
P12111 Collagen alpha-3(VI) chain  Deaths 1.11 0.015 
P07357 Complement component C8 alpha 
chain  
Survivors 1.29 <0.001 
Q02985 Complement factor H-related protein 3  Survivors 1.15 0.049 
P07099 Epoxide hydrolase 1  Deaths 1.17 0.008 
P21333 Filamin-A  Survivors 1.19 0.011 
 37 
P06396 Gelsolin  Survivors 1.12 0.016 
Q8WU03 Glycine N-acyltransferase-like protein 
2  
Survivors 1.53 0.021 
P26927 Hepatocyte growth factor-like protein  Survivors 1.26 0.034 
P04196 Histidine-rich glycoprotein  Survivors 1.18 0.023 
Q14520 Hyaluronan-binding protein 2  Survivors 1.08 0.027 
P01876 Ig alpha-1 chain C region  Deaths 1.24 <0.001 
P01877 Ig alpha-2 chain C region  Deaths 1.21 <0.001 
P01880 Ig delta chain C region  Survivors 1.17 0.002 
P01860 Ig gamma-3 chain C region  Deaths 1.16 0.046 
P01593 Ig kappa chain V-I region AG  Survivors 2.11 0.014 
P01620 Ig kappa chain V-III region SIE  Survivors 1.06 0.040 
P04433 Ig kappa chain V-III region VG 
(Fragment)  
Deaths 1.20 0.345917917 
P80748 Ig lambda chain V-III region LOI  Deaths 1.44 <0.001 
B9A064 Immunoglobulin lambda-like 
polypeptide 5  
Deaths 1.16 0.032 
P29622 Kallistatin Survivors 1.27 <0.001 
P51884 Lumican  Survivors 1.14 0.037 
P61626 Lysozyme C  Survivors 1.19 0.002 
Q96PD5 N-acetylmuramoyl-L-alanine amidase  Deaths 1.08 0.029 
P36955 Pigment epithelium-derived factor  Deaths 1.19 0.015 
P03952 Plasma kallikrein  Survivors 1.13 0.035 
P00747 Plasminogen  Survivors 1.11 0.074 
Q9UK55 Protein Z-dependent protease inhibitor  Deaths 1.20 0.001 
P07988 Pulmonary surfactant-associated 
protein B  
Deaths 1.39 0.006 
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P62820 Ras-related protein Rab-1A  Deaths 1.14 0.019 
P02787 Serotransferrin  Deaths 1.16 0.042 
P02768 Serum albumin  Survivors 1.17 0.029 
P0DJI8 Serum amyloid A-1 protein  Survivors 1.05 0.033 
P27169 Serum paraoxonase/arylesterase 1  Survivors 1.20 0.006 
P04004 Vitronectin  Survivors 1.11 0.024 
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Supplementary Table 2. Correlations of FLNA and SFTPB with structural and functional 
parameters and biomarkers of inflammation, myocardial necrosis and wall strain   
 
 Spearman’s rho  Spearman’s rho  
Variable FLNA P-value SFTPB P-value 
LVEDD* (mm) -0.132 0.043 -0.067 0.309 
LVESD** (mm) -0.056 0.463 -0.148 0.052 
LVEF (%) -0.030 0.626 -0.041 0.498 
E/A ratio†  -0.053 0.647 -0.169 0.139 
CRP (ng/mL) -0.303 <0.001 -0.021 0.734 
Troponin I 
(pg/mL) 
0.006 0.917 0.024 0.699 
ST-2 (ng/mL) -0.035 0.570 0.238 <0.001 
NT-proBNP‡ 
(pg/mL) 
0.170 0.079 0.052 0.593 
 
*Data limited to 78 patients 
**Data limited to 58 patients 
†Data limited to 26 patients 
‡Data limited to 36 patients 
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Supplementary Figure 1. Principal component analysis of HDL proteins
 
(Green: survivors, blue: deaths) 
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Supplementary Figure 2. Biological processes associated with altered HDL proteome
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